Search Within

Isabelle C Riviere

  1. "GSK Faculty"
  2. "Hematologic Malignancies Research"
  3. "Jae Park"
  4. "Xiuyan Wang"
Formats
  1. Meeting Abstract (45)
  2. Journal Article (15)
  3. Research Letter (1)
Groups
  1. Adult Leukemia (61)
  2. Center for Hematologic Malignancies (61)
  3. Department of Medicine (61)
  4. GSK Faculty (61)
  5. Hematologic Malignancies Research (61)
  6. Hematologic Malignancies, Division of (61)

More Groups

People
  1. Jae Park (61)
  2. Xiuyan Wang (61)
  3. Michel Sadelain (56)
  4. Renier Brentjens (54)
  5. Brigitte Senechal (30)
  6. Yvette Bernal (27)

More People

Years
  1. 2023 (4)
  2. 2022 (4)
  3. 2021 (5)
  4. 2020 (1)
  5. 2019 (6)
  6. 2018 (6)

More Years

Publications
  1. Blood (21)
  2. Journal of Clinical Oncology (10)
  3. Molecular Therapy (6)
  4. Haematologica (5)
  5. Hematological Oncology (3)
  6. Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (21)
  2. American Society of Clinical Oncology (10)
  3. Nature Publishing Group (9)
  4. Ferrata Storti Foundation (5)
  5. American Association for Cancer Research (3)
  6. Wiley Blackwell (3)

More Publishers

Results (61)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cooperative CAR targeting to selectively eliminate AML and minimize escape
    Journal Article

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; de Stanchina, E.; Lopez, M.; Ng, M. R.; Fraser, K.; Subklewe, M.; more...
    Cancer Cell (2023)

    Fulltext@MSK | Save
  • Validation of a high-sensitivity assay for detection of chimeric antigen receptor T-cell vectors using low-partition digital PCR technology
    Journal Article

    Arcila, M. E.; Patel, U.; Momeni-Boroujeni, A.; Yao, J.; Chan, R.; Chan, J.; Rijo, I.; Yu, W.; Chaves, N.; Patel, H.; more...
    Journal of Molecular Diagnostics (2023)

    Fulltext@MSK | Save
  • Characterizing the relationship between cellular kinetics and response to support dosing recommendations for Cd19-targeted 19(T2)28z1xx cell therapy
    Meeting Abstract

    Li, J.; Singh, R.; Dey, A.; Sellner, L.; Liu, R.; Dash, A.; Park, J.; Palomba, M.; Mansilla-Soto, J.; Senechal, B.; more...
    Clinical Pharmacology & Therapeutics (2023)

    Fulltext@MSK | Save
  • A phase I study of CD19‐targeted 19(T2)28z1xx CAR T cells in adult patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Palomba, M. L.; Riviere, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Cathcart, E. R.; Liotta, K.; Li, J.; Sellner, L.; Sadelain, M.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A phase I study of CD19-targeted 19(T2)28z1XX CAR T cells in adult patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Park, J. H.; Palomba, M. L.; Rivière, I.; Sikder, D. S.; Senechal, B.; Wang, X.; Bermudez, V. P.; Cathcart, E. R.; Liotta, K.; Joseph, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Target densities in malignant and normal cells determine CAR T cell efficacy and off-target hematotoxicity
    Meeting Abstract

    Haubner, S.; Mansilla-Soto, J.; Nataraj, S.; Kogel, F.; Chang, Q.; De Stanchina, E.; Fraser, K.; Park, J. H.; Wang, X.; Rivière, I.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: A preclinical model and initial clinical experience
    Journal Article

    Palomba, M. L.; Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Rivière, I.; Sadelain, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia
    Research Letter

    Perica, K.; Flynn, J.; Curran, K. J.; Rivere, I.; Wang, X.; Senechal, B.; Halton, E.; Diamonte, C.; Pineda, J.; Bernal, Y.; more...
    Leukemia (2021)

    Fulltext@MSK | Save